David A Liebner, MD
Academic Title: Associate Professor in the College of Medicine
Research Program: Translational Therapeutics
About Me
More info forI am a medical oncologist with a clinical specialization in bone and soft tissue sarcoma. I also serve as an assistant professor of medical oncology and biomedical informatics at The Ohio State University. As a member of the Translational Therapeutics Program at the OSUCCC – James, my research focuses on developing computational tools to improve prognostic and predictive models in sarcoma with the aim of facilitating more personalized cancer treatments. In particular, I’m interested in integrating results from sophisticated tests on patient tumors — including next-generation sequencing, proteomics and metabolimics — with clinical databases in order to help understand what treatments work best in individual patients. As part of this work, I have led the creation of a Sarcoma Registry at the OSUCCC – James to allow us to capture this clinical data in a rigorous manner. I have authored or co-authored numerous medical manuscripts on sarcoma, and I am active in national and international research groups that are dedicated to developing novel treatments for sarcomas. I have served as the principal investigator or co-investigator on nearly 40 clinical studies at Ohio State. I’m inspired by the mission of the OSUCCC – James to achieve a cancer-free world, and feel honored to be a part of that vision. Because each patient is unique, the medical and therapeutic regimens we provide should mirror that, and I believe the better our ability to accurately predict responses and customize treatments, the more positive outcomes we will see. I’m excited about the work we’re doing at the OSUCCC – James, and all of the potential medical breakthroughs to come.
Clinical Expertise
More info for- Skin Cancers
- Sarcoma
- Melanoma
- Soft Tissue Cancers
- Bone Cancer
- Osteosarcoma
Research Interests
More info for- Thyroid Neoplasms
- Sarcoma
- Necrosis
- Carcinoma, Renal Cell
- Neoplasm Metastasis
- Sarcoma, Ewing
- Hemorrhage
- Melanoma
- Osteosarcoma
- Rhabdomyosarcoma
Where I See Patients
More info forThe Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
460 W. 10th Ave. Columbus, Ohio 43210 800-293-5066 Location InformationEducation & Training
More info forFellowship - Hematology & Oncology
- Ohio State University Wexner Medical Center
700 Ackerman Rd, Columbus, OH
Fellowship - Other, Not Listed
- Ohio State University Wexner Medical Center
700 Ackerman Rd, Columbus, OH
Medical School
- State University of New York at Buffalo
3435 Main St, Buffalo, NY
Internship - Internal Medicine
- SUNY at Buffalo-Emergency Medicine GME
100 High St, Buffalo, NY
Residency - Internal Medicine
- SUNY at Buffalo-Emergency Medicine GME
100 High St, Buffalo, NY
- Ohio State University Wexner Medical Center
Academic Office & Contact Information
More info forAcademic Office:
Lincoln Tower 1335
1800 Cannon Dr
Columbus, Ohio 43210Phone:
614-293-9868Email:
liebner.2@osu.eduReviews
More info forPatient Satisfaction Review
The overall patient satisfaction rating is an average of all patient responses to the five questions gathered from the Outpatient Oncology survey, developed by Press Ganey Associates for use in oncology clinics across the country. On behalf of The James, Press Ganey administers the survey to patients who see our providers in an outpatient clinic office. For additional information about the patient satisfaction survey, please visit our
Patient Satisfaction Survey page The comments are submitted by patients and reflect their view and opinions. The comments are not endorsed by and do not necessarily reflect the views of The James.
Publications
More info forSeptember 28, 2024A multicenter, randomized, non-comparative, phase II study of nivolumab ± ipilimumab for patients with metastatic sarcoma (Alliance A091401): expansion cohorts and correlative analyses.
Seligson ND, Chen JL, Goodrich AC, Van Tine BA, Campbell JD, Richards AL, Antonescu CR, Liebner DA, Milhem MM, Streicher H, Tap WD, Schwartz GK, George S, D'Angelo SP
J Immunother Cancer
July 17, 2024Use of neoadjuvant paclitaxel in breast angiosarcoma-Impact on surgical resection and response rates.
Selby LV, Clark E, Chen JL, Tinoco G, Beane JD, Pollock RE, Liebner D, Grignol VP
J Surg Oncol
May 18, 2024Clinical Characteristics, Patterns of Care, and Treatment Outcomes of Radiation-Associated Sarcomas.
Raj R, Kim HG, Xu M, Roach T, Liebner D, Konieczkowski D, Tinoco G
Cancers (Basel)
March 27, 2024Afamitresgene autoleucel for advanced synovial sarcoma and myxoid round cell liposarcoma (SPEARHEAD-1): an international, open-label, phase 2 trial.
D'Angelo SP, Araujo DM, Abdul Razak AR, Agulnik M, Attia S, Blay JY, Carrasco Garcia I, Charlson JA, Choy E, Demetri GD, Druta M, Forcade E, Ganjoo KN, Glod J, Keedy VL, Le Cesne A, Liebner DA, Moreno V, Pollack SM, Schuetze SM, Schwartz GK, Strauss SJ, Tap WD, Thistlethwaite F, Valverde Morales CM, Wagner MJ, Wilky BA, McAlpine C, Hudson L, Navenot JM, Wang T, Bai J, Rafail S, Wang R, Sun A, Fernandes L, Van Winkle E, Elefant E, Lunt C, Norry E, Williams D, Biswas S, Van Tine BA
Lancet
February 6, 2024Scalp Irradiation with 3D-Milled Bolus: Initial Dosimetric and Clinical Experience.
Dibs K, Gogineni E, Jhawar SM, Baliga S, Grecula JC, Mitchell DL, Palmer J, Haglund K, Andraos TY, Zoller W, Ewing A, Bonomi M, Bhateja P, Tinoco G, Liebner D, Rocco JW, Old M, Gamez ME, Chakravarti A, Konieczkowski DJ, Blakaj DM
Cancers (Basel)
January 25, 2024ASO Visual Abstract: Adjuvant Palbociclib May be Associated with Delayed Recurrence in Completely Resected Retroperitoneal Liposarcoma: Results of a Single-Institution Retrospective Cohort Study.
Selby LV, Clark EC, Liebner DA, Chen JL, Tinoco G, Bashian E, Beane JD, Pollock RE, Grignol VP
Ann Surg Oncol
April 7, 2023Clinical markers of immunotherapy outcomes in advanced sarcoma.
Husain M, Quiroga D, Kim HG, Lenobel S, Xu M, Iwenofu H, Chen JL, Verschraegen C, Liebner D, Tinoco G
BMC Cancer
April 3, 2023A Case of Mediastinal Carcinosarcoma With Beta-HCG Production and KRAS Mutation.
Shaker N, Amadi CC, Welliver M, Otterson GA, Liebner DA, Shilo K
Int J Surg Pathol
January 9, 2023Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial.
Hong DS, Van Tine BA, Biswas S, McAlpine C, Johnson ML, Olszanski AJ, Clarke JM, Araujo D, Blumenschein GR, Kebriaei P, Lin Q, Tipping AJ, Sanderson JP, Wang R, Trivedi T, Annareddy T, Bai J, Rafail S, Sun A, Fernandes L, Navenot JM, Bushman FD, Everett JK, Karadeniz D, Broad R, Isabelle M, Naidoo R, Bath N, Betts G, Wolchinsky Z, Batrakou DG, Van Winkle E, Elefant E, Ghobadi A, Cashen A, Grand'Maison A, McCarthy P, Fracasso PM, Norry E, Williams D, Druta M, Liebner DA, Odunsi K, Butler MO
Nat Med
January 1, 2023Case report: Pulmonary synovial sarcoma in a long-term survivor of childhood Hodgkin lymphoma.
Shilo K, Kneuertz PJ, Liebner D, Chen W
Front Oncol
January 1, 2023Sorafenib-Induced Capillary Leak Syndrome.
Kwon H, Odackal J, Husain M, Liebner DA
Case Rep Oncol
March 31, 2022Phase I study of trametinib in combination with whole brain radiation therapy for brain metastases.
Palmer JD, Prasad RN, Fabian D, Wei L, Yildiz VO, Tan Y, Grecula J, Welliver M, Williams T, Elder JB, Raval R, Blakaj D, Haglund K, Bazan J, Kendra K, Arnett A, Beyer S, Liebner D, Giglio P, Puduvalli V, Chakravarti A, Wuthrick E
Radiother Oncol
September 24, 2021Randomized Prospective Trial Exploring the Impact of Structured Journaling in Patients With Sarcoma on the Management of Treatment-Related Adverse Events.
Speece NJ, Xu M, Tinoco G, Liebner DA, Chen JL
JCO Oncol Pract
August 23, 2021Pancreatic enzyme autodigestion of an unresectable retroperitoneal liposarcoma.
Zeh R, Wiseman J, Liebner D, Grignol V
BMJ Case Rep
January 1, 2021A case of multiple synchronously diagnosed brain metastases from alveolar soft part sarcoma without concurrent lung involvement.
Damante MA, Huntoon KM, Palmer JD, Liebner DA, Elder JB
Surg Neurol Int
July 23, 2020A Randomized, Double-Blind, Placebo-Controlled, Phase II Study of Regorafenib vs. Placebo in Advanced/Metastatic, Treatment-Refractory Liposarcoma: Results from the SARC024 Study.
Riedel RF, Ballman KV, Attia S, Loggers ET, Ganjoo KN, Livingston MB, Chow W, Wright J, Ward JH, Rushing D, Okuno SH, Reed DR, Liebner DA, Keedy VL, Mascarenhas L, Davis LE, Ryan C, Reinke DK, Maki RG
Oncologist
June 7, 2020An EWSR1-CREB3L1 Fusion Gene in Extraskeletal Undifferentiated Round Cell Sarcoma Expands the Spectrum of Genetic Landscape in the "Ewing-Like" Undifferentiated Round Cell Sarcomas.
Bissonnette C, Shilo K, Liebner D, Rogers A, Pollock RE, Iwenofu OH
Int J Surg Pathol
June 5, 2020Activity of PD1 inhibitor therapy in advanced sarcoma: a single-center retrospective analysis.
Quiroga D, Liebner DA, Philippon JS, Hoffman S, Tan Y, Chen JL, Lenobel S, Wakely PE, Pollock R, Tinoco G
BMC Cancer
Consulting and Related Relationships
More info forAt The Ohio State University Wexner Medical Center, we support a faculty member’s research and consulting in collaboration with medical device, research and/or drug companies because a faculty member’s expertise can guide important advancements in the practice of medicine and improve patient care. In order to provide effective management of these relationships, the university requires annual disclosures from all faculty members with external interests related to their university responsibilities. As of 09/30/2024, Dr. Liebner has reported relationships with the companies or entities listed below. If you have questions about the relationships listed below, please ask the faculty member. If you have questions about how these relationships are monitored by The Ohio State University Wexner Medical Center, please contact our Compliance Office.
- Aadi Bioscience
Patient Comments
The team has been wonderful every time
Dr Liebner spent a lot of time with me and I did not feel rushed. Excellent doctor!
Dr Liebner is great
Doctor Leibner is an excellent Compassionate and Listener. He is tremendously knowledgeable about my condition. Thankful He is our Oncologist.
Dr Liebner is among the best. His knowledge is reassuring, and his communication skills are exemplary.
The care providers are welcoming, make me feel comfortable in sharing concerns, and I am fully confident that I am receiving exceptional care.
My Guardian Angels !!!
Excellent care and consideration by all
As previously stated Dr Liebner is the best.
Keep doing what your doing
Dr. Liebner always provides the information I need in a way that makes sense. I never feel rushed and he always answers my questions.
Dr. Liebner is an excellent doctor with current information and am impeccable bedside manner.
Fellow and attending physician entertained all questions. Both very adept at explaining in easy terms for understanding.
Dr. Liebner is a great listener. He explains test results well and offers his advice on care that I should receive.
All of my doctors make me feel comfortable.
Exemplary team of professionals.
Dr Liebner is thorough and personable individual. I feel fortunate he is involved in my care.
Superb care
Dr Liebner is empathetic and explains options with clarity. He is the best!
Dr. Liebner's care is excellent. He explains my options and works through medication issues
Dr Liebner answers all questions and does an exceptional job of explaining.
The care provider ranks very high in all regards in that I have complete confidence in his care
Dr. Liebner is knowledgeable and patient. He is passionate in what he does. We are grateful to have such a kind and knowledgeable oncologist.
Very comfortable
Good
Professional, empathetic, active listener, confident, and knowledgeable.
Dr Leibner, Dr. Grignol, and Bridget Hartwell, APRN were all very knowledgeable and reassuring. I appreciate each of their input very much.
Dr. Liebner and Michelle were very thorough!